,67 Methylphenidate (a dopamine transporter blocker) and rosagiline (a monoamine oxidase-B inhibitor) treatments also improved fatigue scores in Parkinson’s disease patients by enhancing the dopaminergic signalling in the striatum.12 This evidence concerns the gene SLC6A3 and Parkinson disease.